Given the significantly increased risk for progression associated with p53 and p16-altered nonmuscle-invasive bladder cancers, patients presenting with such tumours may be better served by early treatments such as immunotherapy, chemotherapy or even cystectomy. This evidence concerns the gene TP53 and neoplasm.